Are you Dr. Maurer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 35 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4650 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-669-2121Fax+1 323-660-7128- Is this information wrong?
Summary
- Dr. Barry Maurer, MD is a pediatric hematologist/oncologist in Los Angeles, California. He is currently licensed to practice medicine in California.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of Southern California/LAC+USC Medical CenterResidency, Pediatrics, 1991 - 1993
Wayne State University School of MedicineInternship, Transitional Year, 1990 - 1991- Wayne State University School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1992 - 2025
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
- N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
- Collecting and Storing Tissue From Young Patients With Cancer Start of enrollment: 2007 Mar 05
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsA phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumorsJacob Stephen Thomas, Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos, David R. Gandara, Heinz Joseph Lenz, Min H. Kang, C. Patric...> ;Cancer Chemotherapy and Pharmacology. 2021 Jan 10
- 3 citationsHydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.Hwang Eui Cho, Barry J. Maurer, C. Patrick Reynolds, Min H. Kang> ;Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2019 Apr 1
- 8 citationsCytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Michael M. Song, Monish Ram Makena, Ashly Hindle, Balakrishna Koneru, Thinh H. Nguyen, Dattesh Verlekar, Hwangeui Cho, Barry J. Maurer, Min H. Kang, C. Patrick Reynolds> ;Anti-Cancer Drugs. 2019 Feb 1
- Join now to see all
Press Mentions
- Kang Receives CPRIT Funding to Support West Texas Pharmacology CoreNovember 9th, 2022
TTUHSC Researchers Publish Preclinical Data on New Drug Combination to Treat NeuroblastomaNovember 8th, 2019
Grant Support
- Novel L-Threo-Sphinganines For Ceramides-Based Cancer TherapyNational Cancer Institute2012
- A Phase I Trial Combining Fenretinide And Safingol To Target Overproduction Of DINational Cancer Institute2011
- Novel Ceramide-Based Chemotherapy For Acute LeukemiaNational Cancer Institute2007
- Novel Ceramide-Based Chemotherapy For Acute LeukemiaNational Cancer Institute2004–2007
- Ppmp As A Ceramide Catabolism Inhibitor For ChemotherapyNational Cancer Institute2003
